Ignite Creation Date:
2024-05-05 @ 6:43 PM
Last Modification Date:
2024-10-26 @ 9:36 AM
Study NCT ID:
NCT00537602
Status:
TERMINATED
Last Update Posted:
2010-02-12
First Post:
2007-09-28
Brief Title:
Miglustat OGT 918 in the Treatment of Cystic Fibrosis
Sponsor:
Actelion
Organization:
Actelion
Study Overview
Official Title:
Single Center Double-blind Randomized Placebo-controlled 2-period2-treatment Crossover Study Investigating the Effect of Miglustat on the Nasal Potential Difference in Patients With Cystic Fibrosis Homozygous for the ΔF508 Mutation
Status:
TERMINATED
Status Verified Date:
2010-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Methodology applied did not meet all criteria required per guidelines
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Cystic fibrosis is a genetic disease caused by mutation of the cystic fibrosis transmembrane conductance regulator CFTR The purpose of the study is to investigate the effects of miglustat on CFTR function in cystic fibrosis patients
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None